Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria

Günter Weiss, Philip E Thuma, George Mabeza, Ernst R. Werner, Manfred Herold, Victor R. Gordeuk

Research output: Contribution to journalArticle

Abstract

To determine whether iron chelation modulates nitric oxide (NO) formation and cell-mediated immune effector function in children with cerebral malaria, serum concentrations were measured of the stable end products of NO, nitrite and nitrate (NO2/NO3), interleukin (IL)-4, -6, and -10, and neopterin in 39 Zambian children enrolled in a placebo-controlled trial of desferrioxamine B and quinine therapy. Mean concentrations of NO2/NO3 increased significantly over 3 days in children receiving desferrioxamine plus quinine but not in those given placebo and quinine. Neopterin levels declined significantly with placebo but not with desferrioxamine. IL-4 levels increased progressively in the placebo group and ultimately decreased in the desferrioxamine group, but the trends were not statistically significant. IL-6 and IL-10 levels were elevated initially and decreased significantly in both groups over 3 days. These data are consistent with the hypothesis that iron chelation therapy in children with cerebral malaria strengthens Th1-mediated immune effector function involving increased production of NO.

Original languageEnglish (US)
Pages (from-to)226-230
Number of pages5
JournalJournal of Infectious Diseases
Volume175
Issue number1
StatePublished - 1997
Externally publishedYes

Fingerprint

Chelation Therapy
Cerebral Malaria
Deferoxamine
Quinine
Nitric Oxide
Iron
Placebos
Neopterin
Interleukin-4
Interleukin-6
Nitrites
Interleukin-10
Nitrates
Serum

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Weiss, G., Thuma, P. E., Mabeza, G., Werner, E. R., Herold, M., & Gordeuk, V. R. (1997). Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria. Journal of Infectious Diseases, 175(1), 226-230.

Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria. / Weiss, Günter; Thuma, Philip E; Mabeza, George; Werner, Ernst R.; Herold, Manfred; Gordeuk, Victor R.

In: Journal of Infectious Diseases, Vol. 175, No. 1, 1997, p. 226-230.

Research output: Contribution to journalArticle

Weiss, G, Thuma, PE, Mabeza, G, Werner, ER, Herold, M & Gordeuk, VR 1997, 'Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria', Journal of Infectious Diseases, vol. 175, no. 1, pp. 226-230.
Weiss, Günter ; Thuma, Philip E ; Mabeza, George ; Werner, Ernst R. ; Herold, Manfred ; Gordeuk, Victor R. / Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria. In: Journal of Infectious Diseases. 1997 ; Vol. 175, No. 1. pp. 226-230.
@article{851443e1d15f4577bc9d3f7417773c96,
title = "Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria",
abstract = "To determine whether iron chelation modulates nitric oxide (NO) formation and cell-mediated immune effector function in children with cerebral malaria, serum concentrations were measured of the stable end products of NO, nitrite and nitrate (NO2/NO3), interleukin (IL)-4, -6, and -10, and neopterin in 39 Zambian children enrolled in a placebo-controlled trial of desferrioxamine B and quinine therapy. Mean concentrations of NO2/NO3 increased significantly over 3 days in children receiving desferrioxamine plus quinine but not in those given placebo and quinine. Neopterin levels declined significantly with placebo but not with desferrioxamine. IL-4 levels increased progressively in the placebo group and ultimately decreased in the desferrioxamine group, but the trends were not statistically significant. IL-6 and IL-10 levels were elevated initially and decreased significantly in both groups over 3 days. These data are consistent with the hypothesis that iron chelation therapy in children with cerebral malaria strengthens Th1-mediated immune effector function involving increased production of NO.",
author = "G{\"u}nter Weiss and Thuma, {Philip E} and George Mabeza and Werner, {Ernst R.} and Manfred Herold and Gordeuk, {Victor R.}",
year = "1997",
language = "English (US)",
volume = "175",
pages = "226--230",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria

AU - Weiss, Günter

AU - Thuma, Philip E

AU - Mabeza, George

AU - Werner, Ernst R.

AU - Herold, Manfred

AU - Gordeuk, Victor R.

PY - 1997

Y1 - 1997

N2 - To determine whether iron chelation modulates nitric oxide (NO) formation and cell-mediated immune effector function in children with cerebral malaria, serum concentrations were measured of the stable end products of NO, nitrite and nitrate (NO2/NO3), interleukin (IL)-4, -6, and -10, and neopterin in 39 Zambian children enrolled in a placebo-controlled trial of desferrioxamine B and quinine therapy. Mean concentrations of NO2/NO3 increased significantly over 3 days in children receiving desferrioxamine plus quinine but not in those given placebo and quinine. Neopterin levels declined significantly with placebo but not with desferrioxamine. IL-4 levels increased progressively in the placebo group and ultimately decreased in the desferrioxamine group, but the trends were not statistically significant. IL-6 and IL-10 levels were elevated initially and decreased significantly in both groups over 3 days. These data are consistent with the hypothesis that iron chelation therapy in children with cerebral malaria strengthens Th1-mediated immune effector function involving increased production of NO.

AB - To determine whether iron chelation modulates nitric oxide (NO) formation and cell-mediated immune effector function in children with cerebral malaria, serum concentrations were measured of the stable end products of NO, nitrite and nitrate (NO2/NO3), interleukin (IL)-4, -6, and -10, and neopterin in 39 Zambian children enrolled in a placebo-controlled trial of desferrioxamine B and quinine therapy. Mean concentrations of NO2/NO3 increased significantly over 3 days in children receiving desferrioxamine plus quinine but not in those given placebo and quinine. Neopterin levels declined significantly with placebo but not with desferrioxamine. IL-4 levels increased progressively in the placebo group and ultimately decreased in the desferrioxamine group, but the trends were not statistically significant. IL-6 and IL-10 levels were elevated initially and decreased significantly in both groups over 3 days. These data are consistent with the hypothesis that iron chelation therapy in children with cerebral malaria strengthens Th1-mediated immune effector function involving increased production of NO.

UR - http://www.scopus.com/inward/record.url?scp=0031015339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031015339&partnerID=8YFLogxK

M3 - Article

C2 - 8985227

AN - SCOPUS:0031015339

VL - 175

SP - 226

EP - 230

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -